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1. Introduction  
Between 1989 and 2004 the prevalence of gestational diabetes mellitus (GDM) in the US 
increased from 1.9% to 4.2% in parallel with the well documented obesity epidemic 
(Getahun et al., 2008; Mokdad et al., 2001). However, an additional 9-20% of pregnant 
women, with a milder form of glucose intolerance which does not meet the diagnostic 
criteria for GDM, may also be at risk of type 2 diabetes, cardiovascular disease and 
problems while pregnant (Stamilio et al., 2004; Mello et al., 1997; Bo et al., 2004; Nordin  
et al., 2006). 
Fetal overgrowth, defined as macrosomia (birth weight >4000g) or large-for-gestational-age 
birth (LGA, birth weight >90th percentile for a given gestational age) increases maternal 
morbidity from operative delivery and also causes serious consequences to the offspring 
including birth trauma, obesity during childhood and type 2 diabetes and metabolic 
syndrome in adult life (Boney et al., 2005; Zhang & Bowes, 1995; Langer, 2000). 
GDM and excessive pregnancy weight gain, especially in obese women are known risk 
factors for fetal overgrowth (Ray et al., 2001; Hillier et al., 2008). Although previous research 
has suggested that metabolic abnormalities are also present in pregnant women with less 
severe hyperglycemia, the clinical implications of milder maternal hyperglycemia are poorly 
described (Chen et al., 2010; Cheng et al., 2006; Nordin et al., 2006).   
The primary objective of this chapter is to use prospective data from a population of low 
income and minority women to examine (i) the influence of maternal hyperglycemia 
including GDM and less severe maternal hyperglycemia on risk of fetal overgrowth; (ii) the 
association of longitudinally measured excessive pregnancy weight gain with risk of fetal 
overgrowth (IOM, 2009); (iii) the independent contribution of gestational hyperglycemia 
and excessive pregnancy weight gain to fetal overgrowth.  
Because gestational hyperglycemia and excess weight gain during pregnancy are preventable 
risk factors, early detection and treatment of mild hyperglycemia and monitoring pregnancy 
weight gain may be important for reducing the risk of LGA, for reducing childhood and later 
obesity and for improving the long term risk for metabolic disease.  
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2. Maternal hyperglycemia and fetal overgrowth 
2.1 Fetal overgrowth 
Fetal growth is dependent on the capacity of mother to supply nutrients and also on the 
capacity of the placenta to transfer these nutrients to the fetus (Oken & Gillman., 2003; 
Ehrenberg et al., 2004). Maternal factors including parity, length of gestation, mother’s adult 
size, and mother’s own birth weight are strongly related to fetal growth and development 
(Langer, 2000). The prevalence of fetal overgrowth was reported as 8-16% from women 
without GDM and 15-40% from women with gestational hyperglycemia (Mello et al., 1997; 
Ostlund et al., 2003; Bo et al., 2004; Gruendhammer et al., 2003).  
2.2 GDM and fetal overgrowth 
Despite different diagnostic criteria, many studies confirmed that GDM increases the risk of 
macrosomia or LGA birth (Ricart et al., 2005; Ray et al., 2001; Ehrenberg et al., 2004). 
Maternal hyperglycemia increases fetal growth via delivery of excess maternal plasma 
glucose to the fetus, which results in fetal hyperinsulinemia and promotes fetal overgrowth 
(HAPO, 2008; Oken & Gillman., 2003). GDM women undergoing intensive diabetic care had 
similar neonatal birth weights and macrosomia rates compared to non-GDM women 
(Ogonowski et al., 2008) and a clinical trial of continuous glucose monitoring in GDM 
resulted in a significant improvement in infant birth weight with a  reduced risk of 
macrosomia (Murphy et al., 2008).  
2.3 Significance of mild gestational hyperglycemia and LGA birth 
2.3.1 Prevalence of mild gestational hyperglycemia 
Recent studies have paid more attention to pregnancy outcomes of women with gestational 
hyperglycemia less severe than overt GDM. The prevalence of mild hyperglycemia (defined 
as abnormal plasma glucose concentration during glucose challenge test with a diagnostic 
oral glucose tolerance test (OGTT) that did not meet the criteria of GDM) in women 
screened for GDM was 32% in Caucasian women (Mello et al, 1997), 25% in Mexican-
Americans (Yogev et al, 2004) and 9% in multiethnic US population where 70% were African 
American (Stamilio et al., 2004). The relatively high prevalence of less severe maternal 
hyperglycemia raises important questions about effects on the fetus since these women are 
not provided the usual diabetic care for GDM. 
2.3.2 The impact of mild gestational hyperglycemia on fetal overgrowth is 
inconsistent  
Studies suggest that an impaired maternal OGTT is associated with adverse maternal-fetal 
outcomes especially risk of macrosomia and LGA birth (Vambergue et al., 2000; Ostlund et 
al., 2003). The degree of maternal glucose intolerance was associated with a graded increase 
in the incidence of fetal macrosomia (Sermer et al., 1995). Moreover, the recent 
hyperglycemia and adverse pregnancy outcome study (HAPO) found a strong association 
of maternal glucose concentrations below levels diagnostic of diabetes with increased infant 
birth weight (HAPO, 2008), but others found no significant increase in the risk of LGA in 
mildly hyperglycemic women (Nordin et al., 2006;  Gruendhammer et al., 2003). Bo et al 
suggested that metabolic syndrome in mid-pregnancy might be an independent predictor of 
macrosomia in women with some degree of gestational hyperglycemia, including GDM and 
mild hyperglycemia without GDM (Bo et al., 2004).  
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Conflicting data on mild hyperglycemia and fetal overgrowth can be, at least in part, due to 
the different population studied and the criteria used for mild hyperglycemia. Although the 
HAPO study included multiple countries and populations and had a large sample size, it 
was focused on developing an international consensus for the diagnosis and treatment of 
carbohydrate intolerance during pregnancy, and was not designed to compare the 
difference in LGA between GDM and less severe hyperglycemic pregnancies (HAPO, 2008). 
Thus, to establish the risk of adverse fetal outcomes in relation to milder degrees of maternal 
hyperglycemia is clinically important, particularly in high risk US populations.    
2.4 The Camden study 
Camden Study is a prospective cohort study of pregnancy outcome and complications in 
young, generally healthy women residing in one of the poorest cities in the continental 
United States (Webster & Bishaw, 2006). Women with serious non-obstetric problems (e.g., 
Lupus, type 1 or 2 diabetes, seizure disorders, malignancies, acute or chronic liver disease, 
drug or alcohol abuse and psychiatric problems) were excluded from participation. The 
sample for this analysis totaled 2,373 pregnant women with live births who enrolled 
between 1996-2006.  
2.4.1 Definition of GDM and mild hyperglycemia non-GDM in Camden study 
The diagnosis of GDM was made using a two-step approach. All participants were initially 
screened by measuring the plasma glucose concentration 1h after a 50-g oral glucose challenge 
test (GCT) at 28±0.1 (mean±SE) weeks’ gestation. A diagnostic OGTT was performed on that 
subset of women exceeding the glucose threshold value (>140 mg/dl). The diagnostic criteria 
for GDM was the Carpenter/Coustan conversion as recommended by the American Diabetes 
Association (ADA) which defines GDM by two or more glucose values over the cut points of 
95,180,155,140 mg/dl at fasting, 1, 2, and 3 hours during a 100g OGTT (American Diabetes 
Association, 2000). Women with a positive GCT and fewer than two abnormal glucose values 
were identified as having an impaired GCT without GDM (impaired GCT non-GDM). All of 
patients diagnosed with GDM obtained dietary counseling and/or insulin treatment for their 
glycemic control; patients with impaired CGT non-GDM were untreated. 
We identified 2,092 women (88.1%) with normal GCT, 182 women (7.7%) with impaired 
GCT non-GDM and 99 women (4.2%) with GDM (table 1). Ethnic composition of the cohort 
was 46% Hispanic, 37.6% African American and 16.6% Caucasian plus others. When the 
maternal characteristics were rank ordered with respect to glucose tolerance status, older 
maternal age, higher pre-pregnant body mass index (BMI), obesity and prior history of 
GDM, all were found to be positively associated with maternal glycemic status (normal 
GCT, impaired GCT non-GDM or GDM) and represented a linear increasing trend in terms 
of severity (p for trend <0.001 for each). 
2.4.2 Maternal hyperglycemia and LGA birth 
LGA is defined as a neonatal birth weight greater than the 90th percentile for gestational age 
that has been adjusted for ethnicity, parity and infant sex (Zhang & Bowes, 1995). Women 
with GDM or impaired GCT without GDM had a ~2-fold increased risk for bearing an LGA 
infant as compared to women with normal GCT (table 2, model 1) after controlling for 
maternal confounding variables and using a standard which adjusted LGA for maternal 
ethnicity, parity and fetal gender. This increased risk persisted after additional adjustments 
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Characteristics All patients Normal GCT 
Impaired 
GCT 
non-GDM
GDM 
N (%) 2373 (100) 2092 (88.1) 182 (7.7) 99 (4.2) 
Age (yr)1 22.1±0.1 21.7±0.1 24.4±0.4 26.3±0.6 
Pre-pregnant BMI (kg/m2)1 25.7±0.1 25.4±0.1 26.6±0.5 29.8±0.8 
BMI categories1  
<18.5 146 (6.2) 141   (6.7) 5   (2.8) 0 
18.5-24.9 1157 (48.8) 1050 (50.2) 82 (45.1) 25 (25.3) 
25-29.9 587   (24.7) 503 (24.0) 50 (27.5) 34 (34.3) 
≥30 483 (20.4) 398 (19.0) 45 (24.7) 40 (40.0) 
Cigarette smoking 440 (18.5) 381(18.2) 39 (21.4) 20 (20.2) 
Ethnicity2  
Hispanic 1089 (45.9) 949 (45.4) 82 (45.0) 58 (58.6) 
African American 891(37.6) 803 (38.4) 67 (36.8) 21 (21.2) 
Caucasian & other 393 (16.6) 340 (16.3) 33 (18.1) 20 (20.2) 
Medicaid  2323 (97.9) 2047 (97.9) 178 (97.8) 98 (99.0) 
Prior GDM in multiparas1 33 (1.4) 15 (0.7) 8  (4.4) 10 (10.0) 
Primiparas2 923 (38.9) 833 (39.8) 60 (33.0) 30 (30.3) 
Data are mean ± SE or n (%). 
Normal GCT, during a glucose challenge test, glucose ≤140mg/dl; Impaired GCT non-GDM, glucose 
>140mg/dl during a glucose challenge test and non-GDM; GDM, gestational diabetes mellitus (same in 
tables 2,4,5). 
1. p for linear contrasts among groups <0.001 from ANOVA, or Mantel-Haenszel chi-square test; 
2. p for linear contrasts among groups <0.05 from Mantel-Haenszel chi-square test. 
Table 1. Characteristics of Study Participants  
for pre-pregnant BMI and net maternal weight gain (net weight gain=total weight gain- 
infant birth weight) in women with impaired GCT non-GDM (Table 2, model 2), but it was 
non-significant in women with GDM. 
 
  LGA AOR (95% CI)1 
 N 
Unadjusted  
% 
Model 12 Model 23 
GDM 99 10.1 2.05 (1.03, 4.10) 1.52 (0.74, 3.13) 
Impaired GCT non-GDM 182 12.1 2.48 (1.50, 4.09) 2.50 (1.50, 4.14) 
Normal GCT 2092 5.3 Reference Reference 
LGA, large-for-gestational age infant; AOR, adjusted odds ratio; 95% CI, 95% confidence interval (same 
as in tables 4-5). 
1 p for linear trend <0.01. 
2 Model 1 was adjusted for age and cigarette smoking in addition to using a standard which adjusted 
LGA for maternal ethnicity, parity and fetal gender. 
3 Model 2 was adjusted for all variables in model 1 with additional adjustment for pre-pregnant BMI 
and net of weight gain (kg) during pregnancy. 
Table 2. Maternal Hyperglycemia and LGA birth 
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2.4.3 What do we learn from the Camden study? 
Complicating the interpretation of previous studies has been the inability to adjust the 
observations for important factors related to fetal growth such as pre-pregnant obesity or 
gestational weight gain, often because the data were not available (Hillier et al., 2008; 
Rosenberg et al., 2005; Aberg et al., 2001). Our study in Camden also differs because of the 
inclusion of several ethnic groups (Vambergue et al., 2000; Bo et al., 2004; Mello et al., 1997). 
With our large cohort, we had the power to control for known potential confounders that 
influence the fetal overgrowth, including pre-pregnant BMI and net gestational weight gain. 
We confirmed that untreated maternal mild hyperglycemia (impaired GCT with one 
abnormal or no abnormal glucose value at OGTT) in otherwise young and healthy  women 
in the US was associated with a 2-3 fold increased risk of delivering an LGA infant (table 2). 
These observations are consistent with previous findings from populations studied 
worldwide by the HAPO group and other studies (HAPO, 2008; Stamilio et al 2004). In 
addition, increased risk of LGA birth in GDM women (all of whom were treated by diet or 
with insulin) was associated with high maternal pre-pregnant BMI.   
3. Pregnancy weight gain and LGA birth 
3.1 Significance of optimal pregnancy weight gain and fetal growth 
To optimize gestational weight gain for both mother and fetus is critical and remains 
controversial. A large number of studies have found that excess gestational weight gain is 
associated with decreased risk of small-for-gestational age birth and with increased risk for 
LGA birth (Oken et al., 2009; Jensen et al., 2005; Hinkle et a., 2010), regardless the definition 
or the scales used for excess pregnancy weight gain (Kiel et al., 2007;  Jain et al., 2007).  
3.2 Weight gain and maternal obesity 
The independent contribution of excess gestational weight gain and maternal obesity on the 
risk of LGA or macrosomia has been extensively investigated (Jensen et al., 2005; Jain et al., 
2007), because obesity is a common problem during pregnancy (Chu et al., 2007; Sebire et 
al., 2001; Rosenberg et al., 2005). Even in women with a normal pre-pregnant BMI, a higher 
pregnancy weight gain was associated with an increased risk of LGA, while a normal 
weight gain by the 1990 The Institute of Medicine (IOM) guidelines was associated with a 
decreased risk of LGA (DeVader et al., 2007). The definition of an optimal gestational weight 
gain in obese pregnancy remains controversial (Nohr et al., 2008). Jain et al observed that 
overweight/obese women who gain weight within the IOM recommendation achieve better 
fetal outcomes (Jain et al., 2007), while others found weight gain within IOM ranges did not 
reduce the risk of LGA among the obese (Dietz et al., 2009). It was suggested that limited or 
no weight gain in more severely obese pregnant women may increase favorable neonatal 
outcomes (Kiel et al., 2007; Jensen et al., 2005). Thus, an optimal gestational weight gain may 
need to be further defined by obesity severity (Hinkle et al., 2010; Oken et al., 2009). 
3.3 What are problems in the research of weight gain during pregnancy?  
There are limited data that link excess pregnancy weight gain measured prior to screening 
for GDM and /or longitudinal gestational weight gain measures through out the pregnancy 
to adverse pregnancy outcomes. In 2009, the IOM published revised gestational weight gain 
guidelines for how much weight a woman should gain during pregnancy to optimize both 
maternal and child outcomes.  The report highlighted the importance of intervention in 
pregnancy to prevent obesity in the post-partum for mother and child (IOM, 2009).  
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3.4 The US Institute of medicine new guidelines for gestational weight gain 
The new 2009 IOM guidelines are based on the WHO BMI (kg/m2) categories (WHO, 1998) 
and include the recommended total pregnancy weight gain (kg) or rates of weight gain 
during the 2nd and 3rd trimester (kg/week). Weight gain below or above the recommended 
range is defined as inadequate or excessive gain, respectively. 
 
Prepregnancy 
BMI 
BMI (kg/m2) 
(WHO) 
Total weight  
gain range 
Rate of weight gain 2nd and 3rd 
trimester (mean, range)2 
  (lbs) (kg) (lbs/wk) (kg/wk) 
Under weight <18.5 28-40 12.5-18.0 1.0 (1.0-1.3) 
0.51 (0.44-
0.58) 
Normal weight 18.5-24.9 25-35 11.5-16.0 1.0 (0.8-1.0) 
0.42 (0.35-
0.50) 
Overweight 25.0-29.9 15-25 7.0-11.5 0.6 (0.5-0.7) 
0.28 (0.23-
0.33) 
Obese (includes 
all classes) 
≥30.0 11-20 5.0-9.0 0.5 (0.4-0.6) 0.22 (0.17-
0.27) 
1 IOM, Institute of Medicine in US. 
2 Calculations assume a 0.5-2kg (1.1-4.4 lbs) weight gain in the first trimester (based on Siega-Riz et. al., 1994; 
  Abrams et al 1995, Carmichael et al 1997). 
Table 3. New recommendations for total and rate of weight gain during pregnancy, by 
prepregnancy BMI (IOM, 2009)1 
3.5 Assessment of pregnancy weight gain  
We explored the associations between gestational weight gain assessed throughout 
pregnancy with LGA using the 2009 IOM guidelines for weight gain during pregnancy.  
Inadequate, adequate and excessive pregnancy weight gain at weeks 24, 28, 32 and at 
delivery was categorized according to IOM recommendations (table 3). Maternal obesity 
was defined as BMI ≥30 (WHO, 1998); height was measured with a stadiometer at entry. 
Gestational duration was based upon gestation from participants’ last normal menstrual 
period confirmed or modified by ultrasound.  Pregnancy weight was measured at week 12, 
24, 28, 32 and at delivery. Total gestational weight gain was computed as the difference 
between weight at delivery and recalled pre-pregnant weight. Gestational weight gain 
during the 2nd and 3rd trimester was computed as the difference between weights measured 
at each visit minuses the weight measured at week 12.  The rate of weight gain was the 
weight gain (kg) divided by gestational age (weeks).   
3.6 Excess pregnancy weight gain measured mid to late gestations and LGA birth 
The proportion of women with excess pregnancy weight gain at weeks 24, 28, and 32 was 
similar to delivery (48.5%, 52%, 54% and 50% respectively). Depending on the gestation, 21-
27% had an adequate weight gain and 22-30% had an inadequate gain throughout the four 
time points.   
Compared to women with adequate weight gain, excessive weight gain was associated with 
a 1.58-2.66 fold  increased risk of LGA birth (table 4) after controlling for all the confounding 
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variables with the exception of pre-pregnant BMI (p for trend <0.0001 for each model). 
Similar results were obtained when additional adjustment for pre-pregnant BMI. In 
addition, women with inadequate weight gain had a reduced risk of LGA birth at week 28 
and 32 (p<0.05).  
3.7 Contribution of Camden data 
These data confirmed that excess pregnancy weight gain throughout the 2ndand 3rd 
trimesters and at delivery significantly increased risk of LGA, whereas inadequate 
pregnancy weight gain reduced LGA risk. The current study has several important 
strengths. Firstly, we used the most recent IOM recommendations (2009) for the estimation 
of excess weight gain by BMI categories and the analysis models were fully adjusted for 
potential confounding, including pre-pregnant BMI. In contrast, more arbitrary criteria were 
used to define excess weight gain in previous studies (Herring et al., 2009; Rosenberg et al., 
2005), and pre-pregnant BMI either was not available or was not adjusted for in the analysis 
(Hillier et al., 2008; Rosenberg et al., 2005). Secondly, there are limited data on longitudinal 
measures of pregnancy weight gain (Herring et al., 2009; Saldana et al., 2006). We used 
multiple measures of pregnancy weight gain starting prior to the screen for GDM. The 
relationship between excess pregnancy weight gain assessed relatively early in pregnancy 
and risk of LGA could be important for preventive strategies. Total weight gain is not an 
ideal measure to evaluate in relation to fetal growth in GDM patients, because most of 
patients are treated and their weight gain is monitored after the diagnosis.   
 
 Week 24 Week 28 Week 32 At delivery 
Weight 
gain 
LGA
(%)
AOR 
(95% CI) 
LGA
(%) 
AOR 
(95% CI) 
LGA
(%) 
AOR 
(95% CI) 
LGA
(%) 
AOR 
(95% CI) 
Adequate 3.5 Reference 5.1 Reference 6.1 Reference 3.6 Reference 
Inadequate 3.2 
0.90 
(0.47,1.71)
2.6 
0.50 
(0.27, 0.95)
2.3 
0.49 
(0.24, 0.98)
2.3 
0.62 
(0.31, 1.25) 
Excessive 8.7 
2.62 
(1.55, 4.43)
8.0 
1.65 
(1.05, 2.61)
7.6 
1.58 
(1.00, 2.50)
9.1 
2.66 
(1.69, 4.19) 
1 Models were adjusted for age and cigarette smoking in addition to using a standard which adjusted 
LGA for parity, ethnicity and infant gender.  
2 p for trend <0.0001 for week 24, 28, 32 and delivery respectively. 
Table 4. Excess pregnancy weight gain and LGA birth1,2 
4. Association of various degree of gestational hyperglycemia, excess 
pregnancy weight gain with LGA birth 
4.1 Does excess gestational weight gain prior to screening GDM predict risk of GDM? 
High gestational weight gain between early and mid pregnancy was positively associated 
with risk of GDM or impaired glucose tolerance (Hedderson et al., 2010; Herring et al., 
2009). In the Camden study, we found a positive association between excess weight gain 
prior to or at the time of screening for GDM (weeks 24 and 28) with increased risk for GDM 
(AOR 1.57, 95% CI 1.01, 2.44 for week 24, AOR 1.94, 95% CI 1.28, 2.95 for week 28). This 
association was not significant at week 32 or at delivery which may suggest an effect of 
treatment and weight monitoring after the diagnosis of GDM.  We did not observe a 
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significant association between excess weight gain and impaired GCT non-GDM (p>0.05 for 
all time points). 
4.2 The association of gestational hyperglycemia and excess weight gain with LGA 
Combined association of gestational hyperglycemia and excess weight gain on the risk of LGA 
has not been examined extensively. Hillier et al observed at GDM screening that macrosomia 
risk was increased across the spectrum of maternal glucose levels and that this relationship 
was further modified by excessive maternal weight gain (Hillier et al., 2008). A weight gain of 
40lbs or more nearly doubled the risk of fetal macrosomia among glucose intolerant women 
including those with GDM. However, results were not adjusted for pre-pregnancy BMI which 
can complicate the relationship between maternal hyperglycemia and pregnancy weight gain. 
Thus, our next goal was to examine the independent and combined contributions of 
hyperglycemia and excess weight gain on risk of LGA.  An analysis stratified by excessive 
weight gain was used to index the influence of various degrees of maternal glycemic status 
on LGA risk, using women with non-excess pregnancy weight gain (adequate and 
inadequate gain combined) and a normal GCT as the reference group.  Our results showed 
that excess weight gain (at week 24, 28, 32 or at delivery) was positively associated with a 2-
6 fold increased risks for delivering an LGA infant (table 5) regardless of whether the 
women were diagnosed with GDM, impaired GCT non-GDM or normal GCT. Furthermore, 
women with non-excess weight gain and an impaired GCT non-GDM also had a 2-3 fold 
increased risk of LGA birth during all of four time points, whereas risk of LGA was not 
increased in the GDM group with non-excess weight gain.  
 
 
Weight gain 
at week 24 
Weight gain 
at week 28 
Weight gain 
at week 32 
Weight gain 
at delivery 
 
LGA
(%) 
AOR 
(95% CI)3 
LGA 
(%) 
AOR 
(95% CI)3
LGA 
(%) 
AOR 
(95% CI)3
LGA 
(%) 
AOR 
(95% CI)3 
Excess weight gain         
GDM 11.5 
4.03 
(1.67, 9.73) 
10.5 
3.31 
(1.39, 7.90)
11.3 
3.20 
(1.34, 7.63)
14.3 
6.07 
(2.58, 14.70) 
Impaired GCT 
non-GDM 
16.0 
6.14 
(3.16, 11.90)
14.6 
4.97 
(2.53, 9.71)
14.1 
4.62 
(2.18, 8.31)
14.9 
6.42 
(3.20, 12.88) 
Normal GCT 7.8 
2.91 
(1.88, 4.48) 
7.2 
2.43 
(1.58, 3.73)
6.8 
2.02 
(1.33, 3.10)
8.2 
3.58 
( 2.29, 5.60) 
Non-excess weight 
gain2 
        
GDM 5.6 
1.64 
(0.37, 7.21) 
6.7 
1.69 
(0.38, 7.50)
5.9 
1.31 
(0.30, 5.71)
4.7 
1.62 
(0.37, 7.11) 
Impaired GCT 
non-GDM 
8.1 
2.78 
(1.17, 6.59) 
9.5 
2.98 
(1.31, 6.77)
9.9 
2.69 
(1.19, 6.08)
9.1 
3.79 
(1.65, 8.68) 
Normal GCT 2.8 Reference 3.1 Reference 3.6 Reference 2.5 Reference 
1  Model was adjusted for age, pre-pregnant BMI and cigarette smoking in addition to using a standard 
which adjusted LGA for maternal ethnicity, parity and fetal gender. 
2 Adequate and inadequate weight gain is combined. 
3 p for trend <0.0001. 
Table 5. Maternal hyperglycemia and LGA infant: Stratified by excess weight gain1 
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4.3 What do we learn? 
These data confirmed that hyperglycemia and excess weight gain are independently 
associated with risk of fetal overgrowth. Women with excess weight gain at any of four 
times in gestation and hyperglycemia, even a mild hyperglycemia, had a substantially 
increased risk of LGA.  Risk of LGA was not increased among gestational diabetics without 
an excessive weight gain but only among the group with impaired GCT non-GDM. Thus, 
excess pregnancy weight gain and hyperglycemia are independent risk factors for LGA.  
5. Conclusion 
By using the most updated IOM guidelines (2009) on pregnancy weight gain, we found that 
healthy, young women with mild but untreated hyperglycemia were at increased risk for 
fetal overgrowth (LGA). The risk of LGA birth in women with GDM, who are treated by 
diet or with insulin after diagnosis, was dependent on maternal pre-pregnant weight.  
Excess pregnancy weight gain assessed longitudinally through out mid to late gestation 
consistently showed strong associations with LGA risk. In addition, excess pregnancy 
weight gain and hyperglycemia appeared to be independent risk factors for LGA. The risk 
for LGA was increased still further in women with excess weight gain, even in those with 
mild hyperglycemia. Because prepregnancy obesity, mild gestational hyperglycemia, and 
excess weight gain during pregnancy are preventable risk factors, these findings suggest 
that early detection and treatment of mild hyperglycemia and monitoring pregnancy weight 
gain during early gestation are both important for reducing the risk of LGA, for reducing 
childhood and later obesity and for improving the long term risk for metabolic disease in 
the offspring.  
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